Africa and India Advance AI-Driven Precision Medicine and Biomanufacturing

Africa's first AI-powered biomanufacturing facility has launched in South Africa, while India is advancing a national BioAI initiative under its Bio-E3 policy to drive precision medicine and sustainable biomanufacturing. Both moves aim to leverage artificial intelligence and genomics to accelerate drug discovery, personalized therapies, and industrial bioprocessing.

IndyGeneUS Bio announced the launch of Africa’s first AI×Bio Factory™ on June 2, 2026, through a collaboration with The Aurum Institute and its subsidiary Global Health Innovations, powered by Oracle Cloud Infrastructure. The facility, established within a former Bayer pharmaceutical site in Johannesburg, aims to generate more than one million African clinico-genomic insights over time. Powered by the proprietary Clinico-Genomic Insight Engine (CGIE™), the platform integrates genomic, clinical, pathology, imaging, and real-world evidence data to support AI-driven drug discovery, precision medicine, biomarker development, and advanced diagnostics. A Memorandum of Understanding has also been signed with Nigeria’s National Biotechnology Research and Development Agency for future collaboration in genomics and sovereign health data infrastructure.

In India, the Department of Biotechnology (DBT) and DBT-BIRAC are driving the BioAI initiative under the Bio-E3 policy, integrating AI with biology to accelerate innovation across healthcare, biomaterials, and agriculture. The initiative has AI infrastructure support via a strategic MoU with the IndiaAI Mission and was highlighted at the India AI Impact Summit 2026. BioAI is positioned as national infrastructure to bring academia, startups, and industry into tighter collaboration to accelerate biomanufacturing outcomes.

India’s genomics milestone includes the completion of the Genome India project, which has sequenced 10,000 Indian genomes to create a high-fidelity reference for the Indian genetic pool. A major expansion to 1,000,000 genomes is expected to be announced soon, with the intent to create rich phenotype and disease models for research, next-generation therapeutics, and precision medicine.

The Bio-E3 policy (Biotechnology for Economy, Environment, and Employment) is a strategic national framework focused on high-performance biomanufacturing. It aims to foster a $150 billion bio-economy, support over 6,000 biotech startups, and position India as a global destination for bio-based products. The policy aligns industrial growth with Net-Zero environmental goals and prioritizes indigenous diagnostic kits tailored to the Indian genetic makeup.

AI is enabling a "design-build-test-learn" loop, allowing researchers to model and refine candidates in silicon before committing to costly wet-lab iterations. This approach includes virtual labs, molecule design workflows, and AI-assisted therapeutic design that provides experimentalists with better starting points. One example discussed is antibody design, where AI enables designing antibodies computationally and then testing them in labs.

These initiatives underscore a global shift toward data-driven, personalized healthcare and sustainable industrial bioprocessing, with AI serving as a central enabler for accelerating discovery and translating research into measurable health outcomes.